

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO RESIGNATION AND CESSATION OF OFFICE OF NON-EXECUTIVE DIRECTOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) pursuant to Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of the Company dated April 27, 2025 regarding, among other things, the resignation and cessation of office of Mr. Hu Baifeng (“**Mr. Hu**”), a non-executive Director of the Company and a member of the strategy committee of the Board.

The Board wishes to announce that Mr. Hu’s voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board was due to reallocation of his primary work responsibilities.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
April 29, 2025

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Jiaqing and Mr. Hu Baifeng as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.